Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Humanized KLKB1 provides a mouse model for evaluating the knockdown efficacy of RNAi therapies

Fengxing Gu, Jianling Huo, Yue Zhang et al. Nov 03, 2025 pp. 7843-7843 10.1182/blood-2025-7843

Abstract Introduction: The KLKB1 gene encodes a glycoprotein that participates in the surface-dependent activation of blood coagulation, fib...

Personalized Desensitization for DSAs in Allogeneic Blood or Marrow Transplantation: Impact on Graft Outcomes and Access to Transplant

Christian Gocke, Marianna Zahurak, Ilias Sinanidis et al. Nov 03, 2025 pp. 510-510 10.1182/blood-2025-510

Abstract Introduction: Donor-specific anti-HLA antibodies (DSAs) increase graft rejection risk in allogeneic blood or marrow transplantation...

A longitudinal study on the impact of hematopoietic stem cell transplantation on sickle cardiomyopathy

Parul Rai, Subodh Selukar, Yu Bi et al. Nov 03, 2025 pp. 6050-6050 10.1182/blood-2025-6050

Abstract Introduction: Maladaptive cardiac remodeling in sickle cell disease (SCD) begins early in childhood, with a high cardiovascular dis...

Low incidence of HTLV-1 infection in Andean highlanders with NFKB1 haplotype

Silvia Mancilla, Luis Malpica, Juan-Carlos Valencia et al. Nov 03, 2025 pp. 7153-7153 10.1182/blood-2025-7153

Abstract Human T-cell lymphotropic virus type I (HTLV-1) is a retrovirus infecting T-lymphocytes recognized as the causative agent of adult...

Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts

Andreas Hochhaus, Susanne Saussele, Valerie Coiteux et al. Nov 03, 2025 pp. 3771-3771 10.1182/blood-2025-3771

Abstract Introduction CML is characterized by a reciprocal translocation of t(9;22)(q34;q11), leading to the BCR::ABL1 fusion gene. Most pati...

TP53-mutated Acute Myeloid Leukemia through a single-cell lens

Sun Loo, Benoit Goutorbe, Michelle Jahja et al. Nov 03, 2025 pp. 5266-5266 10.1182/blood-2025-5266

Abstract Introduction TP53 variants occur more commonly in older patients with therapy-related clonal hematopoiesis, mye...

Genomic determinants and differences of primary and secondary plasma cell leukemia

Mehmet Samur, Hamza Hassan, Qi Yan et al. Nov 03, 2025 pp. 7469-7469 10.1182/blood-2025-7469

Abstract Introduction Plasma cell leukemia (PCL) is a rare, aggressive form of multiple myeloma (MM) defined by the presence of >5% c...

NRAS mutation drives excessive netosis and differentiation syndrome in acute promyelocytic leukemia

Xiaojing Lin, Yuncan Cao, Wenjing Shu et al. Nov 03, 2025 pp. 3472-3472 10.1182/blood-2025-3472

Abstract Background Acute promyelocytic leukemia (APL) is highly curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Howe...

Evolving annual community health worker time allocation to maximize sickle cell disease medical home efficiency

Shirley Johnson, Daniel Sop, Yue Zhang et al. Nov 03, 2025 pp. 6148-6148 10.1182/blood-2025-6148

Abstract Background: Medical center-based Community Health Workers, also known as Patient Navigators (PNs), play a vital...

Microbiota metabolite phenlyacetylglycine alleviates acute graft-versus-host diseases

Yuqing Wang, Lei Liu, Xi Zhang Nov 03, 2025 pp. 4088-4088 10.1182/blood-2025-4088

Abstract Introduction Acute graft-versus-host diseases (aGVHDs) is one of the most important complications after allogenic hematopoietic stem...

Risk assessment of myocarditis in patients undergoing chimeric antigen receptor T-cell therapy: A retrospective cohort analysis

Shatha Elemian, Jia Yi Tan, Ahmad Habbas et al. Nov 03, 2025 pp. 7677-7677 10.1182/blood-2025-7677

Abstract Background: The advent of immunotherapy in oncology has increased the prevalence of immune-related adverse events. Chimeric Antigen...

Pre-clinical efficacy of FLT3/BRAF targeting with novel dual inhibitor PHI3 in FLT3/RAS co-mutated AML

Shikhar Sharma, Anna Skwarska, Evangelia Matenoglou et al. Nov 03, 2025 pp. 5062-5062 10.1182/blood-2025-5062

Abstract Introduction: In AML with FLT3 mutations, FLT3 inhibitors are routinely used in combination with induction chemotherapy in fit pati...

LRP-1 regulates T cell proliferation and activation through global lipid network and loss of LRP-1 eliminates GVHD In Vivo

Dan Li, Iqbal Mahmud, Shengqing Gu et al. Nov 03, 2025 pp. 2306-2306 10.1182/blood-2025-2306

Abstract LRP-1, low-density lipoprotein receptor-related protein, is a member of the LDL receptor family with multi-faced functions in the i...

Droplet digital PCR improves measurable residual disease detection and predicts relapse in KMT2A-rearranged leukemia after allogeneic hematopoietic stem cell transplantation: A prospective study

Ya Luo, Ya-Zhen Qin, Xiaosu Zhao et al. Nov 03, 2025 pp. 3518-3518 10.1182/blood-2025-3518

Abstract Background: KMT2A-rearranged (KMT2A-r) leukemia represents a high-risk subtype marked by aggressive biology and high early relapse r...

Marstacimab prophylaxis in participants with Hemophilia A or B with inhibitors: Results from the Phase 3 BASIS trial

Davide Matino, Suchitra Acharya, Carrie Turich Taylor et al. Nov 03, 2025 pp. 306-306 10.1182/blood-2025-306

Abstract Background Marstacimab is a monoclonal antibody that inhibits tissue factor pathway inhibitor to enhance thrombin generation and re...

Raising pre-transfusion HbS levels from 30% to 50% does not increase ischemic stroke recurrence in sickle cell disease: Results from a long-term single-center study

Karina Tozatto-Maio, João Conrado dos Santos, Leonardo Martins et al. Nov 03, 2025 pp. 4738-4738 10.1182/blood-2025-4738

Abstract Introduction: Exchange transfusion remains the only strategy for the secondary prevention of ischemic stroke in sickle cell disease...

Estimating the United States cure-adjusted prevalence of diffuse large B-cell lymphoma (DLBCL): An epidemiological model

Mahmoud Hashim, Tara Beaulieu, Jackie Kwong et al. Nov 03, 2025 pp. 1885-1885 10.1182/blood-2025-1885

Abstract Introduction: Prevalence reflects both how often a disease occurs and how long patients survive. In diffuse large B-cell lymphoma (...

Risk of cardiovascular disease-related mortality in hematologic malignancy patients: A population-level US retrospective cohort study, 1975-2022

Husayn Ladha, Hetty Carraway, Aaron Gerds et al. Nov 03, 2025 pp. 4497-4497 10.1182/blood-2025-4497

Abstract Background: Cardiovascular disease (CVD) now ranks as a leading cause of non-cancer mortality among cancer patients (pts). However,...

Gut microbiota-related lithocholic acid alleviates cgvhd-induced bronchiolitis obliterans syndrome by suppressing CD4+ T cell TCR signaling without impairing the graft-versus-leukemia effect

Xiaoyan Yue, Hongyu Zhou, Yingying Ding et al. Nov 03, 2025 pp. 820-820 10.1182/blood-2025-820

Abstract Background: Bronchiolitis obliterans syndrome (BOS) is one of the most devastating outcomes of chronic graft-versus-host disease (c...

Megakaryocytes engage in emperipolesis with neutrophils and emperipolesis by the immune MK subset leads to efferocytosis and is exacerbated by CXCR1/2 activation in myelofibrosis

Anna Rita Migliaccio, Mario Falchi, Maria Mazzarini et al. Nov 03, 2025 pp. 4797-4797 10.1182/blood-2025-4797

Abstract Megakaryocyte emperipolesis of neutrophils is increased in the bone marrow of myelofibrosis patients and leads to their death by pa...

Bleximenib or placebo in combination with standard induction and consolidation therapy followed by maintenance for the treatment of patients with newly diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia eligible for intensive chemotherapy: A double-blind Phase 3 study (HOVON 181 AML / AMLSG 37-25)

Marc Raaijmakers, Hartmut Döhner, Dimitri Breems et al. Nov 03, 2025 pp. 1654-1654 10.1182/blood-2025-1654

Abstract Background and Significance Newly diagnosed (ND) acute myeloid leukemia (AML) with KMT2A rearrangement (KMT2Ar) is associated with...

CD22-CAR T cell multiomic features linked to patient outcomes in CD19-CAR resistant large B cell lymphoma

Anne Marijn Kramer, Tara Murty, Yiyun Chen et al. Nov 03, 2025 pp. 566-566 10.1182/blood-2025-566

Abstract Background: Approximately half of patients with relapsed/refractory large B cell lymphoma (R/R LBCL) experience disease progression...

Overcoming CAR T cell resistance in NPM1c and KMT2Ar AML through menin pathway inhibition

Sara Piccinelli, Wallace Bourgeois, Andreia Maia et al. Nov 03, 2025 pp. 2319-2319 10.1182/blood-2025-2319

Abstract Background. Acute myeloid leukemia (AML) remains a clinical challenge due to high relapse rates and limited durable treatment optio...

Efficacy and safety profile of obecabtagene autoleucel as a CAR T-cell therapeutic agent

Jugraj Singh, Gary Batra, Hardik Jain et al. Nov 03, 2025 pp. 7836-7836 10.1182/blood-2025-7836

Abstract Introduction - Obecabtagene autoleucel, a novel chimeric antigen receptor (CAR) T-cell therapy aimed at CD19, is a revolutionary me...

Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma

James Ackley, Sagar Lonial, Damian Green et al. Nov 03, 2025 pp. 3953-3953 10.1182/blood-2025-3953

Abstract Introduction: Multiple myeloma (MM) is the second most common hematological malignancy. Advancements in therapy have resulted in a f...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page